Weisblum Eric's Form 4 filing
Silo Pharma, Inc. (SILO) · filed Dec 15, 2021
- Accession no.
- 0001213900-21-065395
- Filed
- Dec 15, 2021, 1:31 PM ET
- Trade date
- Dec 10-13, 2021
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $3.19K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weisblum EricCIK 0001569077 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +5,000 | $0.1554 | +$777 | 7,694,063 | Direct | |
| Dec 13, 2021 | Common Stock | PPurchaseAcquired | +17,500 | $0.1377F1 | +$2,409.75 | 7,711,563 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.131 to $0.1455. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.